Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

By Wong Pancras  

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 4, 2011-05 ,pp. : 478-492

Springer Publishing Company

Access to resources Recommend Favorite

Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor

By Becker Richard   Alexander John   Li YouFu   Robertson Thomas   Kunitada Satoshi   Spencer Frederick   Yang Hongqiu   Harrington Robert  

Journal of Thrombosis and Thrombolysis, Vol. 18, Iss. 3, 2004-12 ,pp. : 193-197

Springer Publishing Company

Access to resources Recommend Favorite

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

By Hara T.   Yokoyama A.   Morishima Y.   Kunitada S.  

Thrombosis Research, Vol. 80, Iss. 1, 1995-10 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Synthetic direct and indirect factor Xa inhibitors

By Samama M.M.  

Thrombosis Research, Vol. 106, Iss. 3, 2002-05 ,pp. : 267-273

Elsevier

Access to resources Recommend Favorite

Use of Oral Direct Factor Xa Inhibiting Anticoagulants in Elective Hip and Knee Arthroplasty: A Meta-analysis of Efficacy and Safety Profiles Compared with those of Low-Molecular-Weight Heparins

By  

Current Vascular Pharmacology, Vol. 11, Iss. 3, 2013-05 ,pp. : 366-375

Bentham Science Publishers

Access to resources Recommend Favorite